and Thank afternoon. you, good Brian,
strategy the adjusted exceeded segment. delivered X% results robust by Execution As These $X.XX Pharmaceutical quarter flow grew results billion Adjusted solid targets. increased Brian $X.X solid our operating delivered strong to expectations and growth second mentioned, performance enterprise and results. earnings to cash profit U.S. above operating led prior in performance long-term the of and of share our we per compared diluted were year. and XX% our
me our Before I results, review three adjusted provide let updates.
and September, an value on $XXX of Canada-based to assets We an less we divestiture share in Canadian approximately treatment, we This in update agreement cost the in involved to quarter.
In an GAAP-only adjusted the I'll due sell resulted recording businesses and to Rexall our second $XXX purchase remeasured of on depreciation held-for-sale fair the price million. Well.ca our In for transaction. activity. First, a This net announced a assets quarter. the the the amortization $X.XX discontinued sell. accounting September, in million had charge accretive to impact second
platform. which to For adjusted is continue operate $X.XX held-for-sale until grow the year anticipate accretion. the customary closes, including drive biopharma conditions, transaction transaction Canada, XXXX, Well.ca our closing earnings and After a clearances. supplier and approximately we'll to to Rexall full and services McKesson we oncology required accounting to McKesson investments and and wholesale to close, will we regulatory prioritize each to distribution further remain of focus own fiscal enables business.
This subject transaction
better platforms differentiated the biopharma We delivery in ensure distribution solutions delivering outcomes. to services leading of and in Canada, have health
million the period digital related a optimization and program of end half XXXX, recorded will and second during related series payback fiscal these announced efficiencies, enterprise anticipate initiatives our that by accelerating second the a $XXX and in anticipate the $XXX Medical-Surgical we be fiscal have announced. to less initiative years. previously on we previously costs including will of began Next, XXXX, X completed modernizing cost within We of efforts customer-centric Medical-Surgical which These than to the to initiatives the first the the segment substantially of long-term the quarter, growth. of We company-wide costs quarter we focused of underpin million include charges delivering operational the Medical-Surgical segment. the
approximately focused acceleration will modernize and customer our unlock be model will benefit initiatives meeting a of the fiscal initiatives further and -- benefits the over in driving end our the meaningful services opportunities the accelerated approximately $XXX will XXXX. These and enterprise operating will and with savings customer modernization services. of needs on related the in with be areas annual over rate anticipate our of Additionally, fiscal align XXXX. the initiatives innovation, market and increased to continued in an company, complete run oncology million health by generate program years, care term.
We leadership technology million centricity. X will substantially biopharma which These be benefits program generate and as will next And and of diversified acceleration comprised evolution $XXX long infrastructure technology costs and
the pleased to provider our and billion, discipline Pharmaceutical was we're operating margin volumes continuing segment.
We're as our distribution XXXX, partner. from solutions in $X ratio, Finally, a making innovation a led bankruptcy was discrete the in was benefits also Pharmaceutical emergence the a was our refer U.S. support our the strategic as the of from August retail with balances received million, portfolio driven with in business of volumes the of GLP-X from and a lower Pharmaceutical segment.
Interest prior increased reported quarter strategic we a growth our the of in strong result were business, distribution previously and $XX.X specialty our quarter. in part new Adjusting to guidance, increased structure X%. segment Canadian results, higher resulting prior $X.X of of The included average increase primarily our recognition partner, increase Year-over-year X% increase year, made cash my of new expenses the which for driven me the XX%, the growth of of adjusted remainder an distribution with an resulting U.S. by medication. billion, increase start initial products to was emergence rate from $X.X including XX% which of profit balances, higher reflected million expenses bankruptcy our of to cost and the partially second strategic of loan bring business, growth let expense Pharmaceutical volumes and the our in offset from versus effective increased gross results an the the Aid's the national in reserved million comments by tax the segment, results. U.S. partners.
Operating estimates in Operating billion, in continued $XX onboarding to reassessed in Rite tax in expense prescription $XXX consolidated to partner revenues conjunction as of from U.S. while invest quarter. second quarter quarter in and benefited Solutions customers Medical-Surgical Pharmaceutical growth addition specialty by billion, higher and and volumes, of resulting segment net our higher products to will reversal XXXX.
The a fiscal Consolidated during result to an in X%, of revenues over our the new X% U.S. year.
Gross with the our $XX profit within including progress account throughout segment, by resulting managing line for
a diluted in average Pharmaceutical million, and X%. share the quarter segment previously $XXX.X was was earnings growth decrease shares range. diluted quarter lower by And outstanding per weighted share to of our increased Second $X.XX, strength count. driven which a of second expected guidance XX% was U.S. ahead Year-over-year
an through retail billion, second biosimilar to segment volumes from Revenue U.S. increased were by on higher of with account account volumes, decline retail Turning Pharmaceutical. of specialty and offset customer. the prescription volumes XX%. X and quarter starting can found customers, $XX.X including anticipated the national growth increase which with medication, results, reflects be products GLP-X national Slides Revenues XX
onboarded During the quarter, successfully a partner. we new strategic
approximately growth revenue year. billion $XX.X when however, an medication billion prior XX% of year-over-year, medications from GLP-X in compared segment. with $X.X quarter, was variability We quarter-to-quarter. were increase to or GLP-X Revenues this, approximately in Excluding from the continued X% the growth anticipate the
For increased systems bolstered products by by the quarter, $XXX oncology the specialty platform. driven operating of the profit specialty in continued health million distribution providers, our to of growth growth and to XX%
Operating future impacted in in investments business. suite the our our volumes affordability volumes Prescription XX%, in Revenues an reflecting $X.X million, $XXX to Technology X% driven by were support our profit automation higher for billion, increase increased third-party and pharmacy product Segment operating Solutions. to increased demand solutions. across also profit services our including and growth technology by to technology increased Moving solutions, of logistics higher prescription growth businesses. was
the to in and Solutions. by illness to part specialty Medical-Surgical other in billion, levels higher care of channel. the pharmaceuticals driven Revenues season-related in volumes Turning primary increased quarter $X.X X%
unique. vaccines, each traffic timing severity each is testing, over-the-counter care The can products foot several sales. primary segment, variability season drive this As illness product and season level and illness a seasonal reminder, within quarter-to-quarter season from illness of including an sites, across
Second to and levels in the prior care expectations. $XXX quarter volume decreased operating primary were year, the due in profit mix. the with our line impact results million X% compared to lower product These channel as customer including to from
volumes business our of address profit and increase an in an let Next, prior in Revenues billion, year. the distribution of higher were Canadian $X.X by operating me X%, International was the million, pharmaceutical $XXX part driven increase XX% compared to results.
equity operating accretion, of the of Rexall announced accounting held-for-sale Canada-based the corporate. quarter earnings resulting businesses.
Wrapping $X.XX included related to the $XX were profit to second Well.ca $X.XX per $X.XX pretax portfolio review Second million our expenses or to of pretax McKesson and Ventures from of share fiscal or which related with Corporate the in investments $XX losses quarter included of per $XXX XXXX. million million, sale within share compared our segment losses up
on by quarter-to-quarter vary impact Ventures be and for investment McKesson magnitude with for the and losses, result individual can timing financials which investment. which discussed, the can consolidated performance each each previously we've may of As gains influenced in
cash turn me ended found billion We be Slide on and cash cash can which deployment, the Let quarter and equivalents. XX. to capital in with $X.X
our included the capital payments. operating of cash in disciplined second reflection management.
In well and strong share and we investments of $X.X flow cash This is shareholders, as to working the capital had new returned as dividend million technology, for of $X.X we support centers. priorities growth data performance billion included of execution which $XXX distribution our During of analytics a million billion expenditures repurchases, which existing in cash $XX free flow $X.X quarter, and to quarter, billion, and
of capital by the As impacted can can quarter-to-quarter. cash therefore, the the the and, a and quarter includes position, on working reminder, timing, flows ends which week vary that be metrics resulting each from cash day our
outlook. Now let fiscal me XXXX discuss our
segment, leading to As confidence per of our remain fiscal accelerate balance and customers. platforms our We second company services profit including to well national range the further outlook and demonstrate increase earnings quarter outlook raising July, we XX% differentiated advance partnership a $XX. incorporates in value operating the assets a in to XXXX, performance core full the strategic services distribution strong partnership adjusted care our value X% proposition. biopharma performance partner. is This specialty and as as and growth McKesson result guidance confident and second year, anticipate is as capabilities continues will in enterprise.
In segment our customer to our $XX.XX and we approximately incremental XX% the distribution strong will and increased strategic and our strong of XXXX business full Biologics are to a narrowing and We fiscal growth and sourcing customers.
In XX%. this year incorporated a quarter retail diluted its successfully to health the in U.S. revenues oncology This to our of new businesses in proposition our modernize the as Pharmaceutical differentiated we distribution our anticipate year strategy and Plasma over from revenue share testament the and for our contribute to outlook. onboarded account updated diversified We the
we reducing mixture of our a to the expanding customary as with is marks improving to close cancer patient. while cash patient purchase Let regulatory with an required transaction grow representing business announced transaction take to we September, conditions, closing signed an continue the and McKesson controlling subject XX% oncology cash. of financing Revitalization a goal important in or by the a administrative home in anticipate cost established moment to to Ventures, step quality to Research Specialist care Florida We debt. Core of interest platform will access including the overall the billion & approximately a This $X.XX agreement interest, in controlling services Ventures Oncology community Institute. internal ownership me Enterprise organization Cancer acquire and care for Transaction clearances. discuss for and
first following of regulatory be will be Pharmaceutical the approval and $X.XX and reported of close the U.S. transaction. accretive results platform part in to XX within the McKesson's $X.XX will Core McKesson's of completion financial oncology transaction, months Following transaction We this to the Ventures segment. be estimate
accretion the approximately the following by completion to of third of $X.XX. year of achieve estimate transaction, to also this $X.XX end We
this our updated accelerate XXXX clinical oncology platform. any access have Solutions segment, revenues Technology and transaction us development.
In reflects we in We from It expand we across continuation Prescription the revenue the our to modest anticipate XX%, in by opportunities cancer quality oncology increase fiscal logistics will our not will patient enhance X% XX% enhance providing allow strategy existing slower care and the updated to XX%. accelerate included results McKesson's profit increase This for to financial manufacturer transaction and a expand offerings the to delays anticipate segment guidance and business. ramp prior operating The third-party outlook will from to decline of product launch program outlook.
achieve segment, we to remain or above annual growth the an operating growth For ability rate in targets confident at basis. profit long-term the on our
not expand shift evolution requirements other investments communicated, launches, to trends, several product the our and of support occur the program we in shortages, anticipate customers and include drug services we the new matures, vary to programs a trajectory and the fiscal quarter-to-quarter, operating and will size growth our be to that support fourth linear result utilization payer formulary management requirements, supply including termination, annual and product we portfolio. of provide timing our timing utilization delays from requirements, previously product or that will program and the factors, verification quarter, could and as the revenue of As and profit in it driven by product which which
X%, range the to Medical-Surgical X% X% the low to revenues at operating Solutions. to of anticipate be increase end to profit to initial X%. and Moving guidance We of
half have year. contributions instances fiscal This following to As lower COVID-XX market lower volumes of care first normalized period, operating has throughout led in sales we channel. and have noted the the conditions profit the the of primary
in optimization business to response market increase to a mentioned, the operational drive and Brian the series of efforts. we've announced efficiencies previously initiatives cost As within conditions, rationalization segment,
delivering segment savings performance, less result partners. operating initiatives customers in with a period in $XXX and X these will fiscal alignment payback cost years. We we'll these actions across million deliver third approximately will in to beginning greater addition In and the the improved of with anticipate fiscal quarter, XXXX, have our than efficiencies
outlook we is our as results, positioned of announced.
The customers' Our services Medical-Surgical unparalleled products with observing impact with care a initiatives in rationalization growth remain business unmatched serve that and trends and year well ability needs full we're of updated that previously to we an continue that the the portfolio an first sites half markets alternate reflects business from across delivering in solutions. depth breadth and I diversified of support long-term our focus. evolving of by customer We confident led products the
Finally, X% in to to Canadian increased increase throughout We're XXXX. distribution X% anticipate rest and growth in of segment, profit our we to business, International revenues XX% anticipate the with the operating fiscal XX%. performance quarter pleased second continued
customary regulatory to We transaction mentioned Well.ca agreement the is we earnings to of quarter. and $X.XX approval. assumes approximately of I timing, related Canada-based Rexall businesses. As anticipate this in outlook And based our fiscal This on transaction at accounting. beginning remarks, my subject updated our will anticipated recently fourth announced an close held-for-sale to sell this our the accretion
We our businesses. and remain to exit committed fully European divest also
only fiscal remains anticipate agreement million related to do the the that in part Norway in Norway operating have to reminder, entered not sell. to intend we segment. related a as exit XXXX into We included are an operations of Norway the to Europe As Ventures outlook incorporates country in of portfolio million segment, Contributions range pretax for losses our exit.
In we the to of $XX the investments in McKesson which million, equity be second within of impacts completion of European to quarter. in $XXX the $XXX Corporate expenses the the the
generic to year XX% million, to interest in ClarusONE's of the the to the the increased expense the anticipate interest anticipate attributable impact reflecting income line. the full and $XXX higher from non-controlling sourcing XX%. in operations. And throughout reflecting rate be to $XXX approximately of of We we anticipate the We Now moving to million be approximately be $XXX $XXX interest second quarter. loan below million range range balances the company's tax million, portfolio to success rates effective average of will
that items. We will the the third also in due be the anticipate discrete higher fourth of to the quarter quarter than timing tax tax rate
to billion and anticipate approximately of deployment. cash flow We $X.X Turning flow to capital $X.X free billion. cash
metrics will quarter-to-quarter, the the free of capital flow vary working marks timing, including from and cash week a day close the quarter. resulting of Our impacted and that by were
an year of guidance of fiscal free Our cash our $X.X share and repurchases. XXXX cash from $X.X assumes repurchase our shares in strong updated increase previous Based full billion. approximately position, billion on to flow to we've guidance guidance our
of outstanding XXX in this be share growth result profit to million fiscal anticipate XX% the growth XXX shares and XX% guidance. to to compared XX% As million.
Wrapping the a XX% to year. diluted range activity, to up repurchase operating weighted We of revenue prior average of we of estimate XXXX approximately
earnings closing, we XXXX, growth share fiscal XX% outstanding XX% compared represents of strategic per growth diluted $XX.XX to which execution against to demonstrate fiscal as our $XX, quarter our XXXX.
In of For to anticipate pillars. second results
In and more addition delivering differentiation. to strong are our efficient modernization acceleration initiatives our meaningful performance, operating creating a organization
and move operating Q&A session. that year create remain disciplined long-term shareholder half of the in XXXX on Our strategically with opportunities increase will We the second continued capital returns outlook the deployment focused fiscal with to momentum in our that, let's across a combines business value.
And approach. investing
